Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment
Vinson & Elkins served as co-counsel to Reata Pharmaceuticals, Inc. in connection with a $350 million royalty and equity investment in Reata led by funds managed by Blackstone Life Sciences to fund the development and potential commercialization of bardoxolone methyl, an investigational once-daily oral therapy being studied for chronic kidney disease in Alport syndrome, autosomal dominant polycystic kidney disease and other associated potential future indications.
The financing also includes a $50 million investment in 340,793 shares of Reata’s Class A common stock at $146.72 per share. Reata will receive the $350 million investment at closing, which is expected to occur on or before June 24, 2020.
The V&E team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associate Breanna Kelly.
About Vinson & Elkins
For more than 100 years, Vinson & Elkins has provided deep experience in handling transactions, investments, projects, and disputes worldwide. The firm is a trusted adviser to clients in the most important industrial and digital industries. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.
For more information, please speak with our media contacts.
Key Contacts
Related Insights
- Insight
Published in Bloomberg Law
June 21, 2021 - Event RecapJanuary 13, 2021Video